A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT06051695 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
474
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

A2 Biotherapeutics Inc.

Collaborators